Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
Currently, five classes of drug are approved for the treatment of pulmonary arterial hypertension (PAH): phosphodiesterase 5 inhibitors (PDE5i); endothelin receptor antagonists; prostacyclin analogs; the IP receptor agonist selexipag; and the soluble guanylate cyclase (sGC) stimulator riociguat. For...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-03-01
|
| Series: | Pulmonary Circulation |
| Online Access: | https://doi.org/10.1177/2045894019837849 |